New Approaches of PARP-1 Inhibitors in Human Lung Cancer Cells and Cancer Stem-Like Cells by Some Selected Anthraquinone-Derived Small Molecules

Yu Ru Lee, Dah Shyong Yu, Ya Chun Liang, Kuo Feng Huang, Shih Jie Chou, Tsung Chih Chen, Chia Chung Lee, Chun Liang Chen, Shih Hwa Chiou, Hsu Shan Huang

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Poly (ADP-ribose) polymerase-1 (PARP-1) and telomerase, as well as DNA damage response pathways are targets for anticancer drug development, and specific inhibitors are currently under clinical investigation. The purpose of this work is to evaluate anticancer activities of anthraquinone-derived tricyclic and tetracyclic small molecules and their structure-activity relationships with PARP-1 inhibition in non-small cell lung cancer (NSCLC) and NSCLC-overexpressing Oct4 and Nanog clone, which show high-expression of PARP-1 and more resistance to anticancer drug. We applied our library selected compounds to NCI's 60 human cancer cell-lines (NCI-60) in order to generate systematic profiling data. Based on our analysis, it is hypothesized that these drugs might be, directly and indirectly, target components to induce mitochondrial permeability transition and the release of pro-apoptotic factors as potential anti-NSCLC or PARP inhibitor candidates. Altogether, the most active NSC747854 showed its cytotoxicity and dose-dependent PARP inhibitory manner, thus it emerges as a promising structure for anti-cancer therapy with no significant negative influence on normal cells. Our studies present evidence that telomere maintenance should be taken into consideration in efforts not only to overcome drug resistance, but also to optimize the use of telomere-based therapeutics. These findings will be of great value to facilitate structure-based design of selective PARP inhibitors, in general, and telomerase inhibitors, in particular. Together, the data presented here expand our insight into the PARP inhibitors and support the resource-demanding lead optimization of structurally related small molecules for human cancer therapy.

Original languageEnglish
Article numbere56284
JournalPLoS One
Volume8
Issue number2
DOIs
Publication statusPublished - Feb 25 2013
Externally publishedYes

Fingerprint

NAD ADP-ribosyltransferase
Anthraquinones
Poly(ADP-ribose) Polymerases
anthraquinones
lung neoplasms
Non-Small Cell Lung Carcinoma
Lung Neoplasms
Stem Cells
Telomerase
Telomere
Cells
telomerase
Molecules
neoplasms
stems
antineoplastic agents
telomeres
Pharmaceutical Preparations
therapeutics
Neoplasms

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

New Approaches of PARP-1 Inhibitors in Human Lung Cancer Cells and Cancer Stem-Like Cells by Some Selected Anthraquinone-Derived Small Molecules. / Lee, Yu Ru; Yu, Dah Shyong; Liang, Ya Chun; Huang, Kuo Feng; Chou, Shih Jie; Chen, Tsung Chih; Lee, Chia Chung; Chen, Chun Liang; Chiou, Shih Hwa; Huang, Hsu Shan.

In: PLoS One, Vol. 8, No. 2, e56284, 25.02.2013.

Research output: Contribution to journalArticle

Lee, Yu Ru ; Yu, Dah Shyong ; Liang, Ya Chun ; Huang, Kuo Feng ; Chou, Shih Jie ; Chen, Tsung Chih ; Lee, Chia Chung ; Chen, Chun Liang ; Chiou, Shih Hwa ; Huang, Hsu Shan. / New Approaches of PARP-1 Inhibitors in Human Lung Cancer Cells and Cancer Stem-Like Cells by Some Selected Anthraquinone-Derived Small Molecules. In: PLoS One. 2013 ; Vol. 8, No. 2.
@article{4ca14080be624415b1efb0295b763e16,
title = "New Approaches of PARP-1 Inhibitors in Human Lung Cancer Cells and Cancer Stem-Like Cells by Some Selected Anthraquinone-Derived Small Molecules",
abstract = "Poly (ADP-ribose) polymerase-1 (PARP-1) and telomerase, as well as DNA damage response pathways are targets for anticancer drug development, and specific inhibitors are currently under clinical investigation. The purpose of this work is to evaluate anticancer activities of anthraquinone-derived tricyclic and tetracyclic small molecules and their structure-activity relationships with PARP-1 inhibition in non-small cell lung cancer (NSCLC) and NSCLC-overexpressing Oct4 and Nanog clone, which show high-expression of PARP-1 and more resistance to anticancer drug. We applied our library selected compounds to NCI's 60 human cancer cell-lines (NCI-60) in order to generate systematic profiling data. Based on our analysis, it is hypothesized that these drugs might be, directly and indirectly, target components to induce mitochondrial permeability transition and the release of pro-apoptotic factors as potential anti-NSCLC or PARP inhibitor candidates. Altogether, the most active NSC747854 showed its cytotoxicity and dose-dependent PARP inhibitory manner, thus it emerges as a promising structure for anti-cancer therapy with no significant negative influence on normal cells. Our studies present evidence that telomere maintenance should be taken into consideration in efforts not only to overcome drug resistance, but also to optimize the use of telomere-based therapeutics. These findings will be of great value to facilitate structure-based design of selective PARP inhibitors, in general, and telomerase inhibitors, in particular. Together, the data presented here expand our insight into the PARP inhibitors and support the resource-demanding lead optimization of structurally related small molecules for human cancer therapy.",
author = "Lee, {Yu Ru} and Yu, {Dah Shyong} and Liang, {Ya Chun} and Huang, {Kuo Feng} and Chou, {Shih Jie} and Chen, {Tsung Chih} and Lee, {Chia Chung} and Chen, {Chun Liang} and Chiou, {Shih Hwa} and Huang, {Hsu Shan}",
year = "2013",
month = "2",
day = "25",
doi = "10.1371/journal.pone.0056284",
language = "English",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

TY - JOUR

T1 - New Approaches of PARP-1 Inhibitors in Human Lung Cancer Cells and Cancer Stem-Like Cells by Some Selected Anthraquinone-Derived Small Molecules

AU - Lee, Yu Ru

AU - Yu, Dah Shyong

AU - Liang, Ya Chun

AU - Huang, Kuo Feng

AU - Chou, Shih Jie

AU - Chen, Tsung Chih

AU - Lee, Chia Chung

AU - Chen, Chun Liang

AU - Chiou, Shih Hwa

AU - Huang, Hsu Shan

PY - 2013/2/25

Y1 - 2013/2/25

N2 - Poly (ADP-ribose) polymerase-1 (PARP-1) and telomerase, as well as DNA damage response pathways are targets for anticancer drug development, and specific inhibitors are currently under clinical investigation. The purpose of this work is to evaluate anticancer activities of anthraquinone-derived tricyclic and tetracyclic small molecules and their structure-activity relationships with PARP-1 inhibition in non-small cell lung cancer (NSCLC) and NSCLC-overexpressing Oct4 and Nanog clone, which show high-expression of PARP-1 and more resistance to anticancer drug. We applied our library selected compounds to NCI's 60 human cancer cell-lines (NCI-60) in order to generate systematic profiling data. Based on our analysis, it is hypothesized that these drugs might be, directly and indirectly, target components to induce mitochondrial permeability transition and the release of pro-apoptotic factors as potential anti-NSCLC or PARP inhibitor candidates. Altogether, the most active NSC747854 showed its cytotoxicity and dose-dependent PARP inhibitory manner, thus it emerges as a promising structure for anti-cancer therapy with no significant negative influence on normal cells. Our studies present evidence that telomere maintenance should be taken into consideration in efforts not only to overcome drug resistance, but also to optimize the use of telomere-based therapeutics. These findings will be of great value to facilitate structure-based design of selective PARP inhibitors, in general, and telomerase inhibitors, in particular. Together, the data presented here expand our insight into the PARP inhibitors and support the resource-demanding lead optimization of structurally related small molecules for human cancer therapy.

AB - Poly (ADP-ribose) polymerase-1 (PARP-1) and telomerase, as well as DNA damage response pathways are targets for anticancer drug development, and specific inhibitors are currently under clinical investigation. The purpose of this work is to evaluate anticancer activities of anthraquinone-derived tricyclic and tetracyclic small molecules and their structure-activity relationships with PARP-1 inhibition in non-small cell lung cancer (NSCLC) and NSCLC-overexpressing Oct4 and Nanog clone, which show high-expression of PARP-1 and more resistance to anticancer drug. We applied our library selected compounds to NCI's 60 human cancer cell-lines (NCI-60) in order to generate systematic profiling data. Based on our analysis, it is hypothesized that these drugs might be, directly and indirectly, target components to induce mitochondrial permeability transition and the release of pro-apoptotic factors as potential anti-NSCLC or PARP inhibitor candidates. Altogether, the most active NSC747854 showed its cytotoxicity and dose-dependent PARP inhibitory manner, thus it emerges as a promising structure for anti-cancer therapy with no significant negative influence on normal cells. Our studies present evidence that telomere maintenance should be taken into consideration in efforts not only to overcome drug resistance, but also to optimize the use of telomere-based therapeutics. These findings will be of great value to facilitate structure-based design of selective PARP inhibitors, in general, and telomerase inhibitors, in particular. Together, the data presented here expand our insight into the PARP inhibitors and support the resource-demanding lead optimization of structurally related small molecules for human cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=84874517586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874517586&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0056284

DO - 10.1371/journal.pone.0056284

M3 - Article

C2 - 23451039

AN - SCOPUS:84874517586

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 2

M1 - e56284

ER -